• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Left ventricular hypertrophy and left atrial size are associated with ischemic strokes among non-vitamin K antagonist oral anticoagulant users
ConclusionsPrior cerebrovascular events, diabetes, left ventricular hypertrophy, and increased left atrial size are risk factors for developing an IS among NOAC users.
Source: Journal of Neurology - August 7, 2023 Category: Neurology Source Type: research

Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled  trials
ConclusionAll DOACs had a lower risk of ICH than VKAs. In terms of the risk of ICH, DOACs were overall as safe as LMWHs, and apixaban and dabigatran were as safe as aspirin, but rivaroxaban was not. For secondary prevention stroke, the risk of ICH with DOACs was overall lower than warfarin and similar to aspirin, but it should be noted that compared with aspirin, rivaroxaban may increase the risk of ICH. This is the first pair-wise meta-analysis that compares the risk of ICH between DOACs and other antithrombotic drugs in detail across all diseases, which may have certain significance for patients with high risk of ICH to ...
Source: Journal of Neurology - February 17, 2021 Category: Neurology Source Type: research

Idarucizumab administration in emergency situations: the Munich Registry of Reversal of Pradaxa ® in clinical routine (MR REPAIR)
ConclusionIn our study, we have shown that the administration of Idarucizumab is a rare intervention and restricted to patients with severe bleeding complications or ischemic stroke. The clinical outcome of patients who received Idarucizumab in emergency situations was poor.
Source: Journal of Neurology - August 1, 2019 Category: Neurology Source Type: research

Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis
Source: Journal of Neurology - August 16, 2018 Category: Neurology Source Type: research

Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis
Source: Journal of Neurology - February 5, 2017 Category: Neurology Source Type: research